Glaukos Quick Ratio (GKOS) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Glaukos Corp  (NYSE: GKOS)

Glaukos's Quick Ratio

GKOS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.66 below Glaukos Corp average.

Within Medical Equipment & Supplies industry 62 other companies have achieved higher Quick Ratio than Glaukos in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 890 to 1022.

Explain Quick Ratio?
How much Cash & cash equivalents GKOS´s has?
What are GKOS´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GKOS/financial-strength
https://api.csimarket.com/api/v1/companies/GKOS/fundamentals
https://api.csimarket.com/api/v1/companies/GKOS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
GKOS Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 44.8 %
Y / Y Cash & cash equivalent Change 23.3 %
Quick Ratio MRQ 2.66
GKOS's Total Ranking # 1022
Seq. Current Liabilities Change 23.84 %
Seq. Cash & cash equivalent Change 17.75 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 63
Healthcare Sector # 411
Overall Market # 1022


Quick Ratio Statistics
High Average Low
8.32 4.5 0.01
(Sep 30 2020)   (Dec 31 2014)




Financial Statements
Glaukos's Current Liabilities $ 127 Millions Visit GKOS's Balance sheet
Glaukos's Cash & cash equivalent $ 337 Millions Visit GKOS's Balance sheet
Source of GKOS's Sales Visit GKOS's Sales by Geography


Cumulative Glaukos's Quick Ratio

GKOS's Quick Ratio for the trailling 12 Months

GKOS Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 35.27 %
Y / Y Cash & cash equivalent TTM Growth 1.15 %
Quick Ratio TTM 2.81
Total Ranking TTM # 3781
Seq. Current Liabilities TTM Growth 10.3 %
Seq. Cash & cash equivalent TTM Growth 5.72 %


On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $126.73 millions, cumulative Quick Ratio decreased to 2.81 below the Glaukos Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 193 other companies have achieved higher Quick Ratio than Glaukos. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3683 to 3781.

Explain Quick Ratio?
How much Cash & cash equivalents GKOS´s has?
What are GKOS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 194
Healthcare Sector # 869
Within the Market # 3781


trailing twelve months Quick Ratio Statistics
High Average Low
6.55 4.41 2.05
(Jun 30 2022)   (Jun 30 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Orchestra Biomed Holdings Inc   7.16 $ 101.907  Millions$ 14.228  Millions
Envveno Medical Corporation  7.13 $ 18.472  Millions$ 2.589  Millions
Ceribell Inc   6.51 $ 117.467  Millions$ 18.034  Millions
Autonomix Medical Inc   6.13 $ 7.692  Millions$ 1.254  Millions
Iradimed Corporation  6.13 $ 63.288  Millions$ 10.323  Millions
Orasure Technologies Inc  5.90 $ 148.238  Millions$ 25.104  Millions
Perspective Therapeutics Inc   5.09 $ 201.695  Millions$ 39.602  Millions
Beyond Air Inc   4.69 $ 17.121  Millions$ 3.647  Millions
Clearpoint Neuro Inc   4.68 $ 46.184  Millions$ 9.869  Millions
Cvrx inc   4.67 $ 58.746  Millions$ 12.583  Millions
Heartbeam Inc   4.47 $ 6.065  Millions$ 1.358  Millions
Dexcom Inc   4.25 $ 964.800  Millions$ 227.000  Millions
Innovative Eyewear Inc   3.86 $ 3.197  Millions$ 0.829  Millions
Sight Sciences Inc   3.84 $ 77.402  Millions$ 20.137  Millions
Bluejay Diagnostics Inc  3.83 $ 7.380  Millions$ 1.927  Millions
Alpha Pro Tech Ltd   3.78 $ 25.546  Millions$ 6.750  Millions
Hyperfine Inc   3.60 $ 37.872  Millions$ 10.532  Millions
Capsovision Inc   3.55 $ 21.757  Millions$ 6.124  Millions
Profound Medical Corp   3.41 $ 33.343  Millions$ 9.771  Millions
Rxsight Inc   3.40 $ 254.683  Millions$ 74.952  Millions
Omada Health Inc   3.23 $ 243.151  Millions$ 75.379  Millions
Transmedics Group Inc   3.22 $ 492.962  Millions$ 152.857  Millions
Trisalus Life Sciences Inc   3.15 $ 41.057  Millions$ 13.014  Millions
Procept Biorobotics Corporation  3.10 $ 218.369  Millions$ 70.353  Millions
Carlsmed Inc   3.08 $ 56.207  Millions$ 18.237  Millions
Neuropace Inc   3.08 $ 49.431  Millions$ 16.070  Millions
Outset Medical Inc   3.07 $ 136.627  Millions$ 44.453  Millions
Sharps Technology Inc   2.82 $ 7.478  Millions$ 2.650  Millions
Edwards Lifesciences Corporation  2.81 $ 4,683.700  Millions$ 1,664.300  Millions
Mimedx Group Inc   2.81 $ 120.791  Millions$ 43.031  Millions

Date modified: 2026-10-29T10:01:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.